Urogenital Carcinogenesis in Female Cd1 Mice Induced by in Utero Arsenic Exposure is Exacerbated by Postnatal Diethylstilbestrol Treatment.
From: Inorganic Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at National Institute of Environmental Health Sciences, PO Box 12233, 111 Alexander Drive, Research Triangle Park, NC 27709, USA. waalkes@niehs.nih.gov
Cancer research
- Publish Date: Feb 2006
- ISSN: 0008-5472
- Volume: 66
- Issue: 3
- Pages: 1337-45
- Medium: Print
- Language: English
- Citation (JAMA): Waalkes Michael P, Liu Jie, Ward Jerrold M, et al. Urogenital Carcinogenesis in Female Cd1 Mice Induced by in Utero Arsenic Exposure is Exacerbated by Postnatal Diethylstilbestrol Treatment.. Cancer Res. Feb 2006;66:1337-45
Abstract
Transplacental inorganic arsenic carcinogenicity, together with postnatal exposure to diethylstilbestrol or tamoxifen, was studied. Pregnant CD1 mice received 85 ppm arsenic in the drinking water from gestation days 8 to 18 and were allowed to give birth. Groups (n = 35) of female offspring were injected s.c. on postpartum days 1 through 5 with diethylstilbestrol (2 microg/pup/d) or tamoxifen (10 microg/pup/d) and observed for 90 weeks. Arsenic alone induced some urogenital system tumors, including mostly benign tumors of the ovary and uterus, and adrenal adenoma. Diethylstilbestrol alone induced some tumors (primarily cervical) but when given after in utero arsenic, it greatly enhanced urogenital tumor incidence, multiplicity, and progression. For instance, compared with the incidence of urogenital malignancies in the control (0%), arsenic alone (9%), and diethylstilbestrol alone (21%) groups, arsenic plus diethylstilbestrol acted synergistically, inducing a 48% incidence of malignant urogenital tumors. Of the urogenital tumors induced by arsenic plus diethylstilbestrol, 80% were malignant, and 55% were multiple site. Arsenic plus diethylstilbestrol increased ovarian, uterine, and vaginal tumors, and urinary bladder proliferative lesions, including three transitional cell carcinomas. Tamoxifen alone did not increase urogenital tumors or affect arsenic-induced neoplasia but did increase arsenic-induced uroepithelial proliferative lesions. Uterine and bladder carcinoma induced by arsenic plus diethylstilbestrol greatly overexpressed estrogen receptor-alpha (ER-alpha) and pS2, an estrogen-regulated gene. In neonatal uteri, prenatal arsenic increased ER-alpha expression and enhanced estrogen-related gene expression induced by postnatal diethylstilbestrol. Thus, arsenic acts with estrogens to enhance production of female mouse urogenital cancers.
Mesh Headings (Keywords): Animals, Arsenic, Body Weight, Diethylstilbestrol, Drinking, Drug Synergism, Estrogen Receptor alpha, Female, Gene Expression, Genital Neoplasms, Female, Kidney Neoplasms, Maternal-Fetal Exchange, Mice, Pregnancy, Prenatal Exposure Delayed Effects, Tamoxifen, Urinary Bladder Neoplasms, Uterus
Check for Full Text / PubMed Unique Identifier (PMID): 16452187
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.